Meetings - Prova Education

Search for meetings

Meetings 1-9 of 9

CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Multiple dates available
1.00 credit
CME/CE Virtual Event
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Multiple dates available
0.75 credits
CME/CE In-Person & Virtual Event
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 11, 2026
Houston, Texas
1.00 credit
In-Person & Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026
Seoul
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
September 18, 2026
Palo Alto, California
1.50 credits
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
September 23, 2026
Chicago, Illinois
1.50 credits
CME/CE In-Person & Virtual Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
Orlando, Florida
1.00 credit
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
October 10, 2026
New York, New York
1.50 credits
CME/CE In-Person & Virtual Event
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026
New Orleans, Louisiana
1.50 credits